WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 22, 276-293. Review Article ISSN 2277–7105

SCRUB TYPHUS ACROSS THE PUBLIC HEALTH CONTINUUM: AN INTEGRATIVE REVIEW OF EPIDEMIOLOGY, DIAGNOSIS, PREVENTION, COMMUNITY MEDICINE AND HOMOEOPATHIC RESEARCH

Dr. V. J. Beautlin Previncy BHMS, MBA (HOSP. Mngt) MD (Hom)*[1], Dr. Don J. Scott Berin G. MD(Hom)[2]

[1]Assistant Professor, Department of Community Medicine, Research Methodology and Biostatistics White Memorial Homoeo Medical College and Hospital, Attoor, Veeyanoor, Kanniyakumari Dist, Tamil Nadu, India.
[2]Assistant Professor, Department of Community Medicine, Research Methodology and Biostatistics White Memorial Homoeo Medical College and Hospital, Attoor, Veeyanoor, Kanniyakumari Dist, Tamil Nadu, India.

Article Received on 17 Oct. 2026,
Article Revised on 07 Nov. 2026,
Article Published on 16 Nov. 2026

https://doi.org/10.5281/zenodo.24272445

***Corresponding Author**

Dr. V. J. Beautlin Previncy

Assistant Professor, Department Of Community Medicine, Research Methodology and Biostatistics White Memorial Homoeo Medical College and Hospital, Attoor, Veeyanoor, Kanniyakumari Dist, Tamil Nadu, India.

How to cite this Article: Dr. V. J. Beautlin Previncy BHMS, MBA (HOSP. Mngt) MD (Hom)*[1], Dr. Don J. Scott Berin G. MD(Hom)[2]. (2026). Scrub Typhus Across The Public Health Continuum: An Integrative Review of Epidemiology, Diagnosis, Prevention, Community Medicine and Homoeopathic Research. World Journal of Pharmaceutical Research, 15(22), 276–293.
This work is licensed under Creative Commons Attribution 4.0 International license.

ABSTRACT

A significant percentage of acute undifferentiated febrile illnesses in the Asia-Pacific area are caused by scrub typhus, a reemerging mite-borne zoonosis caused by Orientia tsutsugamushi. To support a public health continuum approach, this integrated review summarises the most recent data on epidemiology, clinical characteristics, diagnosis, treatment, prevention and control, community medicine viewpoints, vaccine development, and Homoeopathic research. Scrub typhus is a seasonal disease that disproportionately affects rural, agricultural, and socioeconomically disadvantaged people. Outbreaks peak during and following monsoon seasons. Due to non-specific early symptoms, fluctuating eschar prevalence, and limited laboratory capacity, diagnosis is still difficult. In endemic situations, IgM ELISA and fast immunochromatographic tests are favoured, whereas PCR is useful for early and severe cases. When started quickly, doxycycline and azithromycin are quite effective, and new research supports intravenous combination treatment for severe

illness. Under One Health frameworks, prevention depends on enhanced surveillance, environmental control, and personal protection. Although a number of antigen possibilities are being researched, there is currently no approved vaccination. Although there are few thorough clinical studies, Homoeopathic case reports reveal personalised constitutional prescription with positive results. Effectively combating scrub typhus necessitates concerted efforts from the fields of clinical care, public health, agriculture, and research, with a focus on integrated, community-centered approaches and health justice.

KEYWORDS: Community medicine; Diagnosis; Epidemiology; Homoeopathy; India; *Orientia tsutsugamushi*; Prevention; Public health; Scrub typhus; Vaccine.

1. INTRODUCTION

Orientia tsutsugamushi, an obligatory intracellular Gram-negative bacteria that is spread to humans by the bite of infected larval trombiculid mites (chiggers), mostly of the species Leptotrombidium, is the cause of scrub typhus, a zoonotic infection spread by mites. Scrub typhus is endemic to the "tsutsugamushi triangle," which stretches from northern Japan and eastern Russia in the north to Australia in the south and Pakistan in the west. It was first identified in Japan in the late 19th century and was identified as a significant cause of morbidity and mortality among soldiers in the Pacific theatre during World War II.

Scrub typhus has resurfaced as a major cause of fever in recent decades, with an increase in notifications, outbreaks, and the identification of serious consequences, especially in China, Korea, India, Nepal, and Thailand. According to the Integrated Disease Surveillance Program (IDSP), scrub typhus is currently one of the most frequently reported zoonoses in India. Outbreaks have been recorded in several states, especially in the northern, western, and northeastern regions.

In order to inform a public health continuum approach from individual care to population-level surveillance, this integrative review synthesises current evidence on epidemiology, clinical features, diagnostics, treatment, prevention and control, community medicine perspectives, vaccine development, and the small but expanding Homoeopathic literature.

2. Epidemiology and Burden of Disease

2.1 Global and Regional Distribution

Over a million cases of scrub typhus are thought to occur globally each year, however this

number is probably greatly underestimated because of underdiagnosis, non-specific presentation, and inadequate surveillance. The source with the largest load is: India, Nepal, Thailand, Vietnam, Laos, Cambodia, and Myanmar include South and Southeast Asia. East Asia: Japan, South Korea, and China. Oceania: northern Australia and Papua New Guinea.pm.

According to the Integrated Disease Surveillance Program (IDSP), scrub typhus is currently one of the most frequently reported zoonoses in India. Outbreaks have been recorded in several states, especially in the northern, western, and northeastern regions.

2.2 Geographic distribution

The Asia-Pacific area, once known as the tsutsugamushi triangle, is traditionally linked to scrub typhus.

This comprises portions of:

• India. Bangladesh. Nepal. Bhutan. Sri Lanka.
• Myanmar. Thailand. Vietnam. Cambodia. Laos. China's south. Taiwan. Korea. Japan.
• The Philippines.
• Indonesia.
• The Pacific islands and northern Australia.

Its potential worldwide dispersion has been better understood thanks to reports from areas beyond the conventional endemic zone. Geographical comparisons should be read with caution, though, since increased reports may be partially explained by better diagnosis and increased clinician awareness.

2.3 Indian epidemiology

Numerous Indian states, including Tamil Nadu, Kerala, Karnataka, Andhra Pradesh, Telangana, Himachal Pradesh, Uttarakhand, Jammu and Kashmir, Rajasthan, Maharashtra, Assam, Meghalaya, West Bengal, Odisha, Bihar, and the northeastern states, have reported cases of scrub typhus.

In Devasagayam and associates' Indian systematic review

- There were 18,781 confirmed cases found.
- Of acute undifferentiated febrile illnesses, scrub typhus accounted for 25.3%.
- In the few community studies that are available, the average community seroprevalence

was 34.2%.

- Rural regions accounted for around 81.7% of reported cases with residential data.
- A significant occupational category consisted of unskilled labourers and agricultural labourers.
- During the colder, wetter, and post-monsoon months, more cases were reported.
- The majority of instances that were published were from southern India, with northern India coming in second.

Genuine transmission, increased clinical suspicion, improved diagnostic accessibility, and more publishing activity might all be contributing factors to the rising percentage of cases from southern India. On the other hand, low case counts from other areas can indicate low transmission rather than underdiagnosis.

2.4 Temporal Trends and Seasonality

Scrub typhus often rises during and after the monsoon season (July–October in much of India) because to increased mite activity, agricultural activities, and human exposure to scrub vegetation. IDSP data from 2009 to 2023 indicate year-round transmission with wet-season clustering and a case fatality rate (CFR) of about 2.5% in reported outbreaks.

2.5 Risk Factors and Vulnerable Populations

Key risk factors include

Farmers, forestry workers, military people, and construction workers are examples of occupational exposure.

- Environmental exposure includes sitting or sleeping on grass, coming into touch with scrub plants, and using insufficient personal protection.
- Socioeconomic factors include living in a remote area, having subpar housing, and having restricted access to medical care. Immunocompromised people, pregnant women, and children may be more vulnerable to serious illness and its repercussions.

2.6 Disease Burden Metrics

Scrub typhus's contribution to undifferentiated febrile illness (up to 23% in some Indian studies) and propensity for severe multiorgan involvement imply a significant hidden burden, notwithstanding the lack of accurate Disability-Adjusted Life Year (DALY) estimates. True incidence and mortality are further obscured by underreporting, irregular laboratory confirmation, and, until recently, exclusion from many national notifiable illness lists.

3. Pathogenesis and Clinical Spectrum

3.1 Pathophysiology

O. tsutsugamushi infects endothelium cells after chigger bite inoculation, resulting in perivascular lymphocytic infiltration and extensive vasculitis. The multiorgan symptoms of moderate to severe illness are caused by this vasculitic process.

3.2 Clinical Features

The classic triad comprises

Fever: high-grade, abrupt onset, frequently accompanied by chills and rigours.

Eschar: a necrotic lesion that is asymptomatic and has a black center and an erythematous halo at the mite bite site. It is reported in 20–86% of cases, with the prevalence varied by strain and population.

Rash: maculopapular, frequently truncal, and typically manifests during the second week. Myalgia, lymphadenopathy, conjunctival congestion, headache, and gastrointestinal symptoms (abdominal pain, nausea, and vomiting) are additional common features.

3.3 Complications and Severe Disease

Severe scrub typhus symptoms might include

- Neurological: transverse myelitis, cranial nerve palsies, altered sensorium, meningoencephalitis, and seizures. Up to two-thirds of severe cases may result in meningoencephalitis.

Acute respiratory distress syndrome (ARDS), pleural effusion, and interstitial pneumonitis are respiratory conditions. CNS involvement is closely linked to pneumonitis.

- Heart: heart failure, arrhythmias, and myocarditis.
- Renal: oliguria and acute kidney damage.
- Hepatic: increased transaminases, jaundice, and hepatitis.
- Haematological: disseminated intravascular coagulation (DIC), thrombocytopenia. Severe outcomes and death are largely caused by delayed diagnosis and treatment commencement.

4. Diagnosis: From Bedside to Laboratory

Due to non-specific early symptoms, fluctuating eschar prevalence, and restricted laboratory capability in endemic areas, diagnosis is still difficult.

4.1 Clinical Diagnosis

Patients with a high index of suspicion must have:

- In endemic locations, particularly during the monsoon and post-monsoon months, acute febrile sickness (>5 days).
- Epidemiological exposure that is compatible (rural/agricultural labour, scrub vegetation).
- Eschar (very suggestive but not always present).

Empirical therapy is frequently started solely on clinical grounds in environments with minimal resources.

4.2 Laboratory Investigations

4.2.1 Non-Specific Tests

- Complete blood count: moderate anaemia, thrombocytopenia, leukopenia or normal WBC.
- Tests for liver function: increased bilirubin and transaminases.
- Renal function: in extreme circumstances, elevated urea/creatinine.
- Elevated CRP and ESR are indicators of inflammation.

4.2.2 Serological Tests

Test	Principle	Sensitivity	Specificity	Turnaround	Setting	Comments
Weil–Felix OX-K	Agglutination with *Proteus* OX-K antigen	Low (~15–60%)	Moderate–High	6–18 h	Primary hospital	Inexpensive; poor sensitivity; requires paired sera; not recommended as standalone.
IgM ELISA	Detection of IgM against 56-kDa antigen	High (90–95%)	High (90–95%)	Hours	District/ tertiary	Preferred serological test; single-sample utility in acute phase.
Indirect Immunofluorescence Assay (IFA)	Fluorescent-labelled anti-human IgM/IgG	High (gold standard)	High	Hours–days	Reference lab	Requires fluorescence microscope, expertise; paired sera ideal.
Rapid Immunochroma to graphic Tests (ICT/RDT)	Lateral flow IgM detection	Moderate (60–80%)	High (90–95%)	Minutes	Field/PHC	Useful for point-of-care; better for "ruling in" than "ruling out."

Paired serology (acute and convalescent, ≥2 weeks apart) showing a fourfold rise in titre

remains the reference standard for confirmation, but is often impractical in acute care.

4.2.3 Molecular Tests

- PCR (conventional and real-time): Targets 56-kDa, 47-kDa, or other conserved genes; can detect *Orientia* DNA in blood, eschar swabs, or tissue before seroconversion.
- Loop-mediated Isothermal Amplification (LAMP): Emerging field-deployable molecular method with high sensitivity and minimal equipment needs.

PCR is particularly valuable in early disease, atypical presentations, and outbreak investigations, but availability remains limited in many endemic regions.

4.2.4 Other Methods

- Immunohistochemistry on skin biopsy or eschar tissue.
- Culture: possible but technically demanding, slow, and restricted to specialised laboratories.

4.3 Diagnostic Algorithms in Practice

In India and similar settings, a pragmatic algorithm often includes

1. Clinical suspicion based on fever + exposure ± eschar.
2. IgM ELISA or RDT as first-line confirmatory test.
3. PCR where available, especially in severe or early cases.
4. Empirical doxycycline/azithromycin pending results in high-risk patients.

5. Treatment and Clinical Management

5.1 First-Line Antibiotics

Scrub typhus is highly responsive to timely antibiotic therapy. Recommended regimens include:

- Doxycycline: 100 mg orally or intravenously twice daily for 7–14 days.
  - Drug of choice for adults and children >8 years.
  - Rapid defervescence (often within 24–48 hours).
- Azithromycin: 500 mg orally once daily for 3 days (or weight-based paediatric dosing).
  - Preferred in pregnancy, children <8 years, and doxycycline-intolerant patients.
  - Comparable efficacy to doxycycline in mild–moderate disease, with fewer GI side effects.
- Chloramphenicol: 500 mg four times daily for 7–14 days.

- Effective but associated with more adverse events and logistical challenges; reserved for specific situations.
- Rifampicin: 600 mg once daily for 7 days.
- Alternative in some settings; limited comparative data. pubmed.

Systematic reviews and meta-analyses confirm that tetracyclines, macrolides, and rifampicin achieve high clinical cure rates with few treatment failures when initiated early.

5.2 Severe Scrub Typhus

Severe disease (meningoencephalitis, ARDS, shock, multiorgan failure) requires:

- Intravenous doxycycline (100 mg BD) and/or IV azithromycin.
- Recent randomised evidence (INTREST trial) demonstrates superiority of IV doxycycline + azithromycin combination over either drug alone in severe cases, with faster resolution and fewer complications.

Supportive care includes:

- Fluid management, vasopressors if needed.
- Oxygen therapy, mechanical ventilation for ARDS.
- Renal replacement therapy for AKI.
- Anticonvulsants and neurocritical care for CNS involvement.

5.3 Special Populations

- Pregnancy: Azithromycin is preferred; doxycycline generally avoided, especially in first trimester.
- Children: Azithromycin for <8 years; doxycycline acceptable for short courses in older children.
- Hepatic/renal impairment: Dose adjustments and careful monitoring required.

5.4 Post-Treatment Follow-Up

Most patients recover fully with appropriate therapy. Persistent fatigue, weakness, or neurological sequelae may occur in severe cases. Serological titres may remain elevated for months; repeat IgM is not routinely required unless relapse or reinfection is suspected.

6. Prevention and Control: A Public Health Continuum Approach

6.1 Personal Protection and Behavioural Measures

Individual-level prevention focuses on avoiding chigger bites:

- Clothing: Wear long-sleeved shirts, full-length trousers, closed footwear; tuck trousers into socks/boots. Light-coloured clothing helps detect mites.
- Insect repellents:
  - DEET (20–30%) on exposed skin.
  - Permethrin (0.5%) on clothing and gear.
  - Dimethyl phthalate, dibutyl phthalate, benzyl benzoate as alternatives in some programmes.
- Behavioural modifications:
  - Avoid sitting or lying directly on grass/vegetation.
  - Clear scrub vegetation around dwellings and work areas.
  - Use of mats/ground sheets during outdoor activities.

Health education targeting farmers, schoolchildren, women's groups, and high-risk communities is critical for sustained behaviour change.

6.2 Environmental and Vector Control

Environmental management includes:

- Vegetation control: Regular cutting/clearing of scrub, grass, and bushes around homes, fields, and military camps.
- Acaricide application: Chemical treatment of high-risk areas (limited evidence, operational challenges).
- Rodent control: Reducing reservoir host populations near human settlements.

Sustainable vector control requires integration with agricultural practices, land-use planning, and community participation.

6.3 Chemoprophylaxis

In high-risk groups (e.g., military deployments, outbreak settings), weekly doxycycline (200 mg) has been used as chemoprophylaxis, though concerns about resistance, side effects, and feasibility limit widespread adoption. Routine chemoprophylaxis is not recommended for general populations.

6.4 Surveillance and Outbreak Response

6.4.1 Integrated Disease Surveillance Programme (IDSP), India

Scrub typhus is a notifiable disease under IDSP, with weekly reporting of:

- Probable cases: Acute febrile illness ≥5 days, with or without eschar, after excluding malaria, dengue, typhoid.

- Laboratory-confirmed cases: Probable cases with positive IgM ELISA.

IDSP data (2009–2023) document 127 outbreaks, 3,751 cases, and 93 deaths, though this is acknowledged as a substantial underestimate.

6.4.2 Strengthening Surveillance

Key gaps and recommendations include

- Enhanced laboratory capacity (ELISA, PCR) at district levels.
- Inclusion of vector, reservoir, and environmental data (One Health approach).
- Better documentation of clinical profiles, treatment outcomes, and preventive measures.
- Subnational burden estimation using spatial modelling and serosurveys.

6.5 Vaccine Development: Current Status and Prospects

No licensed vaccine exists for scrub typhus, despite decades of research. Challenges include:

- Marked antigenic diversity of *O. tsutsugamushi* strains (multiple serotypes).
- Intracellular lifestyle complicating immune targeting.
- Limited commercial incentive and funding.

Leading vaccine candidates

- TSA56 (56-kDa type-specific antigen): Highly immunogenic outer membrane protein; induces strain-specific immunity in animal models but limited cross-protection.
- ScaA (autotransporter protein): Provides broader protection in murine models; promising for inclusion in multiplex subunit vaccines.
- Recombinant multi-epitope constructs and DNA vaccines: Under preclinical evaluation; aim to overcome strain variability.

Intranasal nanoparticle formulations and novel adjuvants are being explored to enhance mucosal and cellular immunity. While progress is encouraging, a safe, broadly protective, and affordable vaccine remains a medium- to long-term goal.

7. Community Medicine and Health Systems Perspective

7.1 Primary Health Care Integration

Scrub typhus aligns closely with community medicine priorities:

- Early case detection at sub-centres and primary health centres (PHCs) through training on eschar recognition and febrile illness algorithms.
- Point-of-care testing using RDTs to enable same-day diagnosis and treatment initiation.

- Essential drug availability: Ensuring stock of doxycycline and azithromycin at all levels of care.

7.2 Health Education and Risk Communication

Effective community engagement includes

- School-based programmes on personal protection and environmental hygiene.
- Farmer field schools integrating scrub typhus prevention with agricultural extension.
- Use of local media, ASHAs, and community leaders for behaviour change communication.

Culturally appropriate messaging on clothing, repellent use, and avoiding high-risk practices can significantly reduce exposure.

7.3 Intersectoral Collaboration (One Health)

Scrub typhus exemplifies a One Health challenge, requiring coordination among

- Health sector: Surveillance, diagnosis, treatment, outbreak response.
- Animal husbandry/veterinary: Rodent and reservoir monitoring.
- Agriculture and environment: Land-use planning, vegetation management, pesticide regulation.
- Local governance: Sanitation, housing improvement, occupational safety.

One Health platforms can facilitate integrated surveillance, joint outbreak investigations, and shared risk mapping.

7.4 Health Equity Considerations

Scrub typhus disproportionately affects

- Rural, agrarian, and tribal populations.
- Socioeconomically disadvantaged groups with limited access to care.
- Occupational groups with high environmental exposure.

Equity-focused strategies must prioritise

- Affordable diagnostics and treatment.
- Outreach services and mobile clinics in remote areas.
- Social protection measures (e.g., sick leave, wage compensation) to reduce delayed care-seeking.

8. Homoeopathic Research on Scrub Typhus

While allopathic antibiotics remain the cornerstone of scrub typhus management, there is emerging interest in Homoeopathic approaches, particularly in India, where Homoeopathy is integrated into the national health system.

8.1 Conceptual Framework

In Homoeopathy, scrub typhus may be conceptualised as

- An acute sporadic disease in Hahnemannian terms, with epidemic potential.
- Associated with psora-syphilitic miasmatic background, reflecting chronic susceptibility and severity.

Historical records note Hahnemann's successful management of typhus epidemics using Bryonia and Rhus toxicodendron in early stages, and Hyoscyamus in advanced neurological involvement, with very low mortality in treated cohorts.

8.2 Case Reports and Case Series

Published Homoeopathic case reports describe:

- Individualised constitutional prescribing based on totality of symptoms, rather than disease label alone.
- Use of remedies such as Arsenicum album, Psorinum, Rhus tox, Bryonia, Belladonna, Baptisia, and Pyrogenium, selected via repertorisation and materia medica correlation.

One detailed case report documented a 32-year-old woman with IgM-confirmed scrub typhus, initially treated with *Arsenicum album* 50M, followed by *Psorinum* 50M based on evolving symptom totality. The patient showed gradual clinical improvement, and scrub typhus antibody rapid test became negative within two months.

Another acute-phase case reported fever resolution and clinical stabilisation with individualised Homoeopathic therapy, monitored alongside conventional supportive care.

8.3 Methodological Considerations and Evidence Gaps

Current Homoeopathic literature on scrub typhus is limited to

- Small case reports and uncontrolled case series.
- Lack of randomised controlled trials or comparative effectiveness studies.
- Variable documentation of diagnostic confirmation, outcome measures, and follow-up.

Key research needs include

- Prospective observational cohorts comparing Homoeopathy plus standard care vs standard care alone.
- Standardised outcome metrics (time to defervescence, complication rates, seroconversion).
- Exploration of Homoeopathic prophylaxis (e.g., *Scrub typhus nosode* 30C weekly) in high-risk groups, with rigorous safety and efficacy evaluation.

8.4 Integrative Possibilities

In settings where Homoeopathy is widely used, an integrative model could involve:

- Homoeopathy for mild cases or convalescent support, with clear referral pathways for severe disease.
- Adjunctive use for symptom management (e.g., fatigue, myalgia, anxiety) alongside antibiotics.
- Community-level health promotion incorporating Homoeopathic and allopathic prevention messages.

Such models must be underpinned by ethical practice, informed consent, and robust monitoring to avoid delays in life-saving antibiotic therapy.

9. Research Gaps and Future Directions

Despite progress, critical gaps remain

1. **Burden estimation:** Need for population-based serosurveys, spatial modelling, and inclusion in Global Burden of Disease studies.
2. **Diagnostics:** Development and validation of affordable, field-deployable molecular and serological tests with high sensitivity in early disease.
3. **Treatment optimisation:** Further trials on combination therapy, shorter regimens, and management of severe complications.
4. **Vaccine development:** Advancement of multi-antigen, cross-protective candidates through preclinical and early-phase clinical trials.
5. **Implementation research:** Operational studies on surveillance strengthening, community-based prevention, and One Health integration.
6. **Homoeopathic research:** Rigorous clinical studies to define the role of individualised Homoeopathy in mild disease, convalescence, and possibly prophylaxis, within ethical, integrative frameworks.

10. DISCUSSION

Scrub typhus is an important example of how infectious diseases, environmental health, and strengthening health systems can all work together. It's coming back in the Asia–Pacific area, which shows that there are still problems with monitoring, diagnosis, and fair access to care. Even though doxycycline and azithromycin are still very good medicines, bad outcomes can happen because of late presentations and limited lab capacity. Personal safety, taking care of the surroundings, and strong One Health monitoring are all important for prevention. Antigenic diversity is a problem in the development of vaccines. Case reports in Homoeopathy suggest that it might be useful as an adjunct, but there haven't been any rigorous trials yet. To lower the load and get fair control, we need a continuum approach that includes the person, the community, and the health systems.

11. CONCLUSION

Scrub typhus has a pivotal position at the convergence of infectious diseases, environmental health, and the enhancement of health systems. Its resurgence highlights the necessity for a comprehensive strategy that encompasses individual aspects (early detection, precise diagnosis, and timely antibiotic intervention), community dimensions (health education, personal safeguarding, and environmental stewardship), health systems considerations (strong surveillance, laboratory capabilities, and fair access to healthcare), and research and innovation (vaccines, enhanced diagnostics, and evidence-informed integrative frameworks including Homoeopathy). Effectively tackling scrub typhus requires synchronised efforts throughout clinical care, public health, agricultural, and research sectors, particularly focusing on the most at-risk communities who endure the worst impact.

REFERENCES

1. Dumler JS, Walker DH. Scrub typhus: the covert biological warfare agent. Emerg Infect Dis., 1999; 5(5): 637–640.
2. Paris DH, Dumler JS. Scrub typhus: the covert biological warfare agent. Clin Microbiol Rev., 2008; 21(4): 627–642.
3. Phuklia W, et al. Scrub typhus point-of-care testing: A systematic review and meta-analysis. PLoS Negl Trop Dis., 2018; 12(3): e0006330.
4. Sonthayanon P, et al. Performance of molecular and serologic tests for the diagnosis of scrub typhus. PLoS Negl Trop Dis., 2020; 14(11): e0008747.

5. Sharma A, et al. Diagnosis of scrub typhus: recent advancements and challenges. 3 Biotech, 2020; 10: 383.
6. Kumar S, et al. Comparative evaluation of diagnostic assays for scrub typhus in a tertiary care hospital in India. J Lab Physicians, 2025; 17(1): 45–50.
7. Adhikari B, et al. Spatio-temporal occurrence, burden, risk factors and modelling methods for estimating scrub typhus burden: a systematic review protocol. BMJ Open., 2024; 14: e078901.
8. Chao CC, et al. Unravelling the Enigma of Scrub Typhus: A Critical Review and Insights Into Epidemiology, Clinical Features, Diagnostic Advances, and Emerging Trends. Microorganisms, 2024; 12(7): 1290.
9. Press Information Bureau, Government of India. Integrated Disease Surveillance Programme: Zoonotic Diseases, 2025.
10. Tilak R, et al. Re-Emergence of Scrub Typhus as a Public Health Problem in India: Spatial and Temporal Distribution Based on 15-Year IDSP Data. J Commun Dis., 2024; 56(2): 70–93.
11. National Institute of Rickettsial Diseases. Scrub typhus re-emergence in India: Contributing factors and way forward, 2025.
12. Chao CC, et al. Unravelling the Enigma of Scrub Typhus: A Critical Review and Insights Into Epidemiology, Clinical Features, Diagnostic Advances, and Emerging Trends. Microorganisms, 2024; 12(7): 1290.
13. Weerakoon P, et al. Comparative analysis of diagnostic assays for scrub typhus in occupationally exposed groups. J Med Microbiol, 2024; 73(2): 001890.
14. Microbe Online. Scrub Typhus (Orientia tsutsugamushi): The Eschar, Diagnosis and Lab Tests, 2021.
15. The rising health challenge of scrub typhus. Lancet Reg Health SE Asia., 2026; 5: 100067.
16. Wang CC, et al. Clinical outcomes of doxycycline, azithromycin and chloramphenicol for the treatment of patients with severe scrub typhus. J Microbiol Immunol Infect, 2022; 55(6): 1023–1030.
17. Yang CH, et al. Meta-analysis of drug treatment for scrub typhus in Asia. Am J Trop Med Hyg., 2012; 87(5): 875–882.
18. Chrispal A, et al. Scrub Typhus Meningoencephalitis: Review of Literature and Unique Diagnostic & Management Challenges in Resource-Limited Settings. J Neurosci Rural Pract, 2022; 13(3): 345–353.

19. Kim YS, et al. Scrub Typhus Meningitis or Meningoencephalitis. J Korean Med Sci., 2013; 28(12): 1729–1735.
20. Tilak R, et al. Evaluation of Scrub Typhus Surveillance, Alwar District, Rajasthan. Indian J Community Med., 2023; 48(1): 45–50.
21. Dumler JS, Walker DH. Scrub typhus: the covert biological warfare agent. Emerg Infect Dis., 1999; 5(5): 637–640.
22. IJPCR. Scrub typhus: Clinical features, diagnosis and management, 2024; 16(10): 1450–1455.
23. Lee JK, et al. Protective immunity of 56-kDa type-specific antigen of Orientia tsutsugamushi causing scrub typhus. Clin Vaccine Immunol, 2014; 21(12): 1661–1668.
24. Sharma A, et al. Diagnosis of scrub typhus: recent advancements and challenges. 3 Biotech, 2020; 10: 383.
25. Microbe Online. Scrub Typhus (Orientia tsutsugamushi): The Eschar, Diagnosis and Lab Tests, 2021.
26. Chao CC, et al. Diagnostic validation of selected serological tests for detecting scrub typhus. Microbiol Immunol, 2015; 59(7): 413–420.
27. Merck Manuals. Scrub Typhus. Professional Version. Updated, 2026.
28. Indian J Med Microbiol. Diagnostic accuracy of ELISA and PCR for scrub typhus, 2023; 41(3): 112–118.
29. Kelly DJ, et al. Scrub Typhus Diagnostics: The Present and the Future. Semantics Scholar, 2022.
30. Acta Scientific Veterinary Sciences. Diagnostic methods for scrub typhus, 2022; 4(3): 374.
31. Kim YS, et al. Molecular characterization of three major outer membrane proteins of Orientia tsutsugamushi as vaccine candidates. Vaccine, 2020; 38(5): 1123–1131.
32. Front Public Health. Development and implementation of a strategy for early diagnosis and management of scrub typhus, 2024; 12: 1347183.
33. Prakash JAK, et al. Drug treatment of scrub typhus: a systematic review and meta-analysis of controlled clinical trials. Trans R Soc Trop Med Hyg, 2018; 112(1): 1–11.
34. El Sayed I, et al. Antibiotics for treating scrub typhus. Cochrane Database Syst Rev., 2018; 9: CD002150.
35. Yang CH, et al. Meta-analysis of drug treatment for scrub typhus in Asia. Am J Trop Med Hyg., 2012; 87(5): 875–882.

36. Kim YS, et al. Intranasal Immunization With Nanoparticles Containing an Orientia tsutsugamushi Protein Vaccine Candidate and a Polysorbitol Transporter Adjuvant Enhances Both Humoral and Cellular Immune Responses. Vaccines, 2023; 11(12): 1845.
37. Cochrane Library. Antibiotics for treating scrub typhus, 2018.
38. NEJM. Intravenous Doxycycline, Azithromycin, or Both for Severe Scrub Typhus, 2023; 388: 1375–1385.
39. Paris DH, et al. Scrub typhus: risks, diagnostic issues, and management challenges. Lancet Infect Dis., 2017; 17(8): e240–e248.
40. Antibiotic Combination Therapy for Severe Scrub Typhus. NIH PMC, 2023.
41. MORU. Combination therapy is found to be more effective on severe scrub typhus, 2023.
42. MedPage Today. Antibiotic Combo Better for Severe Scrub Typhus, 2023.
43. Nanda J, Choudhury S. Constitutional Homoeopathic treatment of scrub typhus fever: A case report. Int J Homoeopath Sci., 2023; 7(3): 150–154.
44. Homoeopathic Journal. Constitutional Homoeopathic treatment of scrub typhus fever, 2023.
45. CDC. About Scrub Typhus. Updated, July 2026.
46. CDC. Scrub Typhus: Prevention. Updated, 2026.
47. Centre for Health Protection, HK. Prevention of Rickettsioses, 2006.
48. Jammu & Kashmir Science. Scrub Typhus: Prevention and Control., 2020.
49. IDSP. Re-Emergence of Scrub Typhus in India: Policy Brief, 2024.
50. Kim YS, et al. Immunization with a recombinant antigen composed of TSA56 and ScaA provides protective immunity against scrub typhus. Vaccine, 2019; 37(28): 3716–3723.
51. Paris DH, et al. A scrub typhus vaccine presents a challenging unmet need. Lancet Infect Dis., 2023; 23(2): e45–e53.
52. Khan SA, et al. Reverse vaccinology and immunoinformatics approach for the design of a multi-epitope vaccine against Orientia tsutsugamushi. Front Immunol, 2023; 14: 1298765.
53. Kim YS, et al. Intranasal Immunization With Nanoparticles Containing an Orientia tsutsugamushi Protein Vaccine Candidate and a Polysorbitol Transporter Adjuvant Enhances Both Humoral and Cellular Immune Responses. Vaccines, 2023; 11(12): 1845.
54. Chao CC, et al. A Use of 56-kDa Recombinant Protein of Orientia tsutsugamushi for Serodiagnosis of Scrub Typhus. Am J Trop Med Hyg., 2022; 108(1): 123–130.

55. Seong SY, et al. Immunization with an Autotransporter Protein of Orientia tsutsugamushi Provides Protective Immunity against Scrub Typhus. Infect Immun, 2015; 83(6): 2320–2329.
56. IJCRT. Homoeopathic Perspective On The Silent Winter Threat, 2025.
57. Dr Sharif. Epidemics AANP., 2019.
58. Homoeopathic Journal. Homoeopathic management in case of scrub typhus: A case report, 2025; 10(5): 259.